Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 6
2018 11
2019 7
2020 12
2021 9
2022 7
2023 9
2024 10
2025 14
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Immune checkpoint inhibitor-induced lichenoid drug eruption-sparing scar burns.
Truong K, Chamberlin CV, Kim J, Carlino MS, Araujo RR. Truong K, et al. Australas J Dermatol. 2024 Mar;65(2):163-166. doi: 10.1111/ajd.14192. Epub 2023 Nov 27. Australas J Dermatol. 2024. PMID: 38009870
The authors present a striking case of a patient experiencing a lichenoid drug eruption secondary to immunotherapy, curiously sparing scarred skin from past burns. We observed vastly higher amounts of inflammatory lymphoid cells staining for PD-1; 70% in skin …
The authors present a striking case of a patient experiencing a lichenoid drug eruption secondary to immunotherapy, cur …
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Ellis SR, et al. J Am Acad Dermatol. 2020 Oct;83(4):1130-1143. doi: 10.1016/j.jaad.2020.04.105. Epub 2020 Apr 29. J Am Acad Dermatol. 2020. PMID: 32360716 Free PMC article. Review.
Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that block cytotoxic T-lymphocyte-associated antigen-4, programmed cell death protein 1, or programmed cell death ligand 1 show improved and sustained responses in pati …
Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that block cytotoxic T-lymphocyte-associat …
Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M, Chiu MN, Pilkhwal Sah S. Bhardwaj M, et al. Cutan Ocul Toxicol. 2022 Mar;41(1):73-90. doi: 10.1080/15569527.2022.2034842. Epub 2022 Feb 20. Cutan Ocul Toxicol. 2022. PMID: 35107396 Review.
INTRODUCTION: The therapeutic use of humanised monoclonal programmed cell death 1 (PD-1) (pembrolizumab, and nivolumab) and programmed cell death ligand-1 (PD-L1) (atezolizumab, avelumab, durvalumab) immune checkpoint inhibitors (ICPi) as potent antica …
INTRODUCTION: The therapeutic use of humanised monoclonal programmed cell death 1 (PD-1) (pembrolizumab, and nivolumab) and programme …
Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V. Sibaud V. Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3. Am J Clin Dermatol. 2018. PMID: 29256113 Review.
The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1)] represents a major breakthrough in cancer thera …
The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 ( …
Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management.
Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Muntyanu A, et al. J Cutan Med Surg. 2021 Jan-Feb;25(1):59-76. doi: 10.1177/1203475420943260. Epub 2020 Aug 3. J Cutan Med Surg. 2021. PMID: 32746624 Review.
Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid organ malignancies. ...Cutaneous irAEs are the most common, arising in up to 34% of patients on PD-1 inhibitors and 43% to 45% on CTLA-4 inhibitors. The most commo …
Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid organ malignancies. ...Cutaneous irAE …
[Lichenoid drug reactions].
Merk HF, Vanstreels L, Megahed M. Merk HF, et al. Hautarzt. 2018 Feb;69(2):116-120. doi: 10.1007/s00105-017-4117-y. Hautarzt. 2018. PMID: 29372264 Review. German.
Lichenoid drug reactions are rare compared to typical morbilliform drug exanthema or urticaria. ...Recent observations included associations with novel drugs such as biologics (e. g. tumour necrosis factor antagonists) and immune checkpoint i …
Lichenoid drug reactions are rare compared to typical morbilliform drug exanthema or urticaria. ...Recent observations …
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M, Sibaud V. Lacouture M, et al. Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39. doi: 10.1007/s40257-018-0384-3. Am J Clin Dermatol. 2018. PMID: 30374901 Free PMC article. Review.
Immune checkpoint inhibitors (ICIs) most frequently induce nonspecific maculopapular rash, but also eczema-like or psoriatic lesions, lichenoid dermatitis, xerosis, and pruritus. ...ICIs typically induce oral lichenoid reactions and xeros …
Immune checkpoint inhibitors (ICIs) most frequently induce nonspecific maculopapular rash, but also eczema-like or psor …
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.
Lacouture ME, Goleva E, Shah N, Rotemberg V, Kraehenbuehl L, Ketosugbo KF, Merghoub T, Maier T, Bang A, Gu S, Salvador T, Moy AP, Lyubchenko T, Xiao O, Hall CF, Berdyshev E, Crooks J, Weight R, Kern JA, Leung DYM. Lacouture ME, et al. Clin Cancer Res. 2024 Jul 1;30(13):2822-2834. doi: 10.1158/1078-0432.CCR-23-3431. Clin Cancer Res. 2024. PMID: 38652814 Free PMC article.
PURPOSE: Immune-related cutaneous adverse events (ircAE) occur in 50% of patients treated with checkpoint inhibitors, but the underlying mechanisms for ircAEs are poorly understood. EXPERIMENTAL DESIGN: Phenotyping/biomarker analyses were conducted in 200 patients …
PURPOSE: Immune-related cutaneous adverse events (ircAE) occur in 50% of patients treated with checkpoint inhibitors, but the …
Immune checkpoint inhibitor associated lichenoid eruptions: a review of non-steroidal systemic maintenance therapies.
Tran R, Toulmin SA, Allais BS, Brag K, Iriarte C. Tran R, et al. Support Care Cancer. 2025 Oct 28;33(11):985. doi: 10.1007/s00520-025-10054-2. Support Care Cancer. 2025. PMID: 41148453 Review.
Lichenoid eruptions (LEs), characterized by mucocutaneous lesions mimicking lichen planus, are one of the most common cirAEs, occurring in up to 17% of patients receiving immunotherapy. ...While oral corticosteroids are effective in improving lichenoid eru …
Lichenoid eruptions (LEs), characterized by mucocutaneous lesions mimicking lichen planus, are one of the most common cirAEs, …
82 results